Introduction
Cardiomyopathy and consequential heart failure are leading causes of death worldwide. [1] [2] [3] The main hallmark of heart failure is a loss of cardiomyocytes, which is often followed by scar formation and compensatory alterations of remote cardiac tissue, also known as adverse cardiac remodelling. Conceptually, the ideal therapeutic strategy would be to replace dead myocardium with newly formed cardiomyocytes that are electromechanically coupled to the pre-existing healthy tissue. However, today's treatment options are still focused on myocardial salvage rather than replacement. 4 Recently, substantial effort has been invested in studying various stem and progenitor cell populations from external sources to assess their capacity to help the failing heart tissue. Cell transplantation strategies aiming to administer autologous bone marrow cells were proven safe but resulted in only modest functional improvements. [5] [6] [7] To date, two clinical studies have used intracoronary injection of c-kit þ cardiac cells (SCIPIO study) 8 and cardiosphere-derived cells (CADUCEUS study) 9 in patients after myocardial infarction. While both studies showed significantly reduced cardiac scar formation, the CADUCEUS study described no substantial functional benefits, while the SCIPIO study documented a modest but significant increase in the ejection fraction. 8, 9 However, considering our current knowledge, the reported effects of the infused cells might be more due to indirect paracrine interactions than to de novo cardiomyogenesis. 10, 11 Several other clinical trials are underway, which will further clarify the mechanism of action of cell therapy. In addition, cardiomyocytes that have differentiated from various sources, such as induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs) and directly reprogrammed cells, have been successfully used in animal models of heart disease, [12] [13] [14] but the safety and efficacy of these strategies need to be demonstrated in human trials. Although the adult mammalian heart has been traditionally viewed as a terminally differentiated organ, several species, including certain amphibians and zebrafish, retain the ability to promote cardiomyogenesis well into adulthood. [15] [16] [17] [18] [19] Beyond injury-induced myocyte renewal, emerging evidence supports the notion that new cardiomyocytes are continuously born in the adult mammalian heart under homeostatic circumstances, although controversial results have been published regarding the possible sources and generation rates of these cells, which have been fuelling active scientific debate. 20 Accordingly, another attractive approach for direct therapeutic intervention in cardiac disease would be to promote the innate cardiac regenerative capacity of the mammalian heart by stimulating the yet undiscovered molecular pathways and cellular mechanisms underlying this phenomenon. [21] [22] [23] [24] To determine whether this strategy is rational and realistic, it is essential to explore the magnitude and dynamics of cardiomyocyte renewal in the human heart.
Cycling cardiomyocytes
Studying cardiomyocyte renewal in humans has been technically challenging and has led to controversial results; therefore, there is an ongoing debate about the magnitude of this process. Mitotic figures in human cardiomyocytes were already reported in the 1920s. 25, 26 However, these studies did not change the prevailing view of the human heart as a post-mitotic organ, mainly because of the absence of a substantial regenerative response to cardiac injuries. In the late 1990s these findings were revived by reports demonstrating an increase in cell cycle activity in diseased hearts based on the presence of mitotic spindles and cell cycle markers, such as Ki- 67. 27,28 These results suggested that the human heart can completely renew within 5 years. 29 However, neither cell cycle markers nor mitotic spindles provide definite evidence for cardiomyocyte proliferation. 20, 30 Instead, non-productive cell cycle activity, leading to polyploidy and binucleation but not to effective cytokinesis, can be observed during physiological heart growth as well as in several cardiac diseases, which can substantially bias estimates of the turnover rates that exclusively rely on the detection of the above-mentioned markers. [31] [32] [33] [34] [35] The functional significance of cardiomyocyte endoreplication in homeostasis and disease remains unclear; nevertheless, it is possible that the increased amount of genomic DNA contributes to a more efficient transcription machinery, providing proteins that support the enhanced metabolic activity and structural needs of cardiac cells undergoing hypertrophic transformation. 36 A different yet equally problematic approach is to estimate myocyte renewal by quantifying apoptotic and necrotic myocytes. 37 Although there is no doubt that human cardiomyocytes undergo apoptosis in the diseased myocardium and during homeostasis, [38] [39] [40] the length of time that the apoptotic phenotype is present has to be precisely determined to establish the magnitude of cell death and thus the replacement required to maintain a constant number of cardiomyocytes. Estimates of apoptotic durations range from a few hours to days, making it impossible to accurately predict the renewal rates of myocytes. [41] [42] [43] While the number of studies showing cardiomyocyte proliferation has been growing, inconsistent data on its magnitude and time course have made it difficult to evaluate the therapeutic potential of this process. 20 To overcome the limitations of these strategies, 14C birth dating has helped provide a more integrated model for the dynamics of cell generation in human hearts. 22, 44 The existence of an innate proliferative capacity, which has been supported by studies based on this novel methodology, might be the basis for future therapeutic strategies that activate regenerative pathways and enhance cardiomyocyte renewal in the human heart. 47 Radiocarbon incorporated in the tissues of a living organism decays at a rate determined by the half-life of the isotope (5740 years). Therefore, the age of biological materials can be estimated based on this decay value and the amount of 14 C remaining in the organic sample at a certain time point. Retrospective birth dating of human cells with a lifetime of less than a century would not be possible given the long half-life of 14 C. However, the dramatic increase in the atmospheric 14 C caused by above-ground nuclear bomb tests conducted by the superpowers in the 1950s and 1960s increased the sensitivity of radiocarbon dating to a degree that allows for age determination with a temporal resolution of 1-2 years. 48, 49 This method has been proven adequate to establish the age of various biological materials, including carotid plaques, 50 hair, bones, 51 and dental enamel, 52,53 for forensic purposes.
Formed when cosmic rays interact with molecular nitrogen, 14 C is naturally present in the Earth's atmosphere. In the next reaction step, radioactive carbon dioxide is formed, which enters the food chain via plants that convert carbon dioxide into organic material during photosynthesis. Radiocarbon eventually reaches the human body and is incorporated into genomic DNA upon each cell division. As all living animals, including humans, constantly exchange carbon with the biosphere, the genomic 14 C concentrations parallel the atmospheric 14 C levels with a negligible food lag of less than 1.5 years 54 ( Figure 1 ).
When a cell undergoes its last cell division, this 14 C circulation stops and the amount of 14 C integrated in the genomic DNA remains virtually constant. The precise date when a certain cell population was generated can thus be determined by comparing its genomic 14 C concentration with the environmental levels, making use of the unique, spike-like shape of the atmospheric 14 C curve around the time of the nuclear bomb tests [55] [56] [57] ( Figure 2A and B). Radiocarbon isotope can be measured with accelerated mass spectrometry, which normally requires carbon levels in the range of milligrams. However, carbon masses in genomic DNA obtained from sorted nucleus populations are typically around a few micrograms, therefore sample preparation techniques need to be optimized for this purpose. 58 Moreover, due to the low abundance of 14 C even after the above ground nuclear bomb tests (on average, only one 14 C isotope is present in every 15th cell), it will never be possible to establish the age at the single-cell level with this method. 55 
Cardiomyocyte turnover in humans
Radiocarbon birth dating could successfully establish, for the first time, the age of cardiac cells. 22, 44 Analysing hearts from patients born before the sudden increase in atmospheric 14 C, we could clearly demonstrate that heart muscle renewal continues at least until the third decade of life. Because cardiomyocytes are surrounded by other cell types with a much higher proliferative capacity, unequivocal identification and stringent isolation of cardiomyocytes was a prerequisite for accurate age determination of these cells. We chose to isolate cardiomyocyte nuclei instead of intact cells because this strategy was the most efficient when using archived frozen material. 34, 59, 60 We successfully validated three independent markers to identify and separate cardiomyocyte nuclei in human and rodent heart samples. 34, 59, 60 Nuclear-localized cardiac troponins I and T 44 and pericentriolar material 1 (PCM-1) 60 identify most, if not all, C is naturally generated in the atmosphere by the action of cosmic rays on nitrogen, above-ground nuclear tests conducted during the Cold War significantly contributed to its environmental level. In the atmosphere, 14 C reacts with oxygen to form CO 2 , which then gets incorporated into plants through photosynthesis. The carbon content of plants is transferred into the human body via the food chain such that the 14 C levels in tissues mirror the atmospheric 14 C concentrations. With every cell division, 14 C is integrated into newly synthetized DNA in amounts proportional to its atmospheric level at any given time. Due to the stability of nuclear DNA, the measured genomic 14 C concentration can be used to establish the age of human cardiomyocytes. C values gained from individuals born before the nuclear bomb tests correspond to two distinct time points (Points 1 and 2). Since the incorporation of environmental 14 C might have occurred during the rise and/or the fall of the curve, the precise age of the cell population cannot be determined with certainty based exclusively on these results. (B) However, in individuals born after the nuclear tests, the measured 14 C levels unambiguously determine the age of the cell population (Point 1).
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cardiomyocyte nuclei in neonatal and adult mammalian hearts. [61] [62] [63] [64] [65] [66] Using either of these isolation strategies, 14 C birth dating demonstrated that cardiomyocyte DNA was younger than the respective individual. 22, 44 However, DNA synthesis with premature cycle exit, resulting in polyploidy, has been reported to occur during physiological heart growth 22, 24, 33 and in cardiac pathologies, including ischaemic heart disease, 32 pathological hypertrophy, 67 and congenital heart disease. 68 Therefore, it was critical to include the time course of polyploidization in the mathematical model to estimate renewal rates. Additionally, to obtain a direct measure of cardiomyocyte formation, we selectively enriched diploid cardiomyocyte nuclei to estimate the rate of cell renewal independent of polyploidy. 22, 44 Data gained from this type of 14 C analysis and a comprehensive time course analysis of binucleation in human cardiomyocytes provided compelling evidence for cardiomyocyte turnover in the adult human heart. 22, 44 Dynamics of cardiac cell turnover in humans
We performed 14 C birth dating and design-based stereology to establish a comprehensive model of the generation and exchange dynamics of cardiomyocytes in the human heart. 22 The number of cardiomyocytes in the left human ventricle estimated by designbased stereology reached the maximum value (3.2 ± 0.75 billion cells) 1 month after birth 22 ; therefore, the later increase in volume and weight during physiological heart growth can mainly be attributed to hypertrophic growth of cardiomyocytes. This finding agrees with earlier stereological studies that show no further increase in cardiomyocyte number after the perinatal period. 69 The unique possibility of establishing the age of cells through 14 C birth dating allows for the generation of mathematical models to describe age distributions within cell populations, which can be used to infer their turnover dynamics. 70 These mathematical scenarios are based on the birth and death rates of cells in the analysed population. Each scenario defines a set of parameters, such as the change in cell number, preferential cell death or renewal. The scenario that best fits the experimental data gained from heart nucleus samples has been chosen as the model that most accurately describes the dynamics of cell turnover 22, 44, 71, 72 ( Figure 3A and B) . Based on our results, we predicted that endothelial and mesenchymal cells are rapidly exchanged in young adults with birth rates of 20% per year for the former and 5% per year for the latter. In contrast, we found much lower agedependent renewal of cardiomyocytes with the highest turnover during the first two decades of life, corresponding to rates of approximately 1% per year at the age of 20, declining to lower than 0.5% per year in elderly individuals 22, 44 ( Figure 3B) . Although the average renewal rates are relatively low during a human's lifetime, approximately 39% of all cardiomyocytes are replaced by post-natally generated myocytes in the left ventricle, and 36% of these cells are already exchanged by the age of 10 years 22 ( Figure 4A and B).
In contrast to our data, a recent study using a similar stereological strategy found that physiological heart growth is accompanied by cardiomyocyte number expansion. 24 Our results, combining 14 C birth dating and stereology, support a continuous renewal of the cardiomyocyte population in which cell birth is counterbalanced by cell death, maintaining a constant cardiomyocyte number throughout an individual's adult life. Challenges of cardiomyocyte labelling and 
sampling strategies might account for the discrepancies between the two reports. 22 Moreover, our findings disagree with earlier data reporting turnover rates up to 50% per year. 29, 73, 74 As discussed before, these previous approaches relied on assumptions based on the frequency and duration of apoptosis and cell cycle activity of cardiomyocytes, 29 number of cells expressing putative stem cell markers, 74 or incorporation of thymidine analogues in patients with malignant diseases. 73 These approaches have substantial shortcomings, as previously described 20, 44, 75 ; therefore, they need to be interpreted with caution. With 14 C birth dating, we could show that the human heart retains its ability to generate new cardiomyocytes, even in middle-aged and older individuals. This finding has important consequences for our understanding of heart homeostasis and disease. Tissue plasticity in the heart is not only based on myocyte hypertrophy often linked to post-mitotic cardiomyocyte endoreplication but also depends on a continuous exchange of cardiomyocytes. A potential loss of the heart's capacity to generate new cardiomyocytes would result in a loss of more than one billon myocytes over a human's lifetime. To compensate for this loss, pre-existing cardiomyocytes should substantially increase in size to maintain the contractility of the heart. This process, however, would only be efficient for a limited amount of time, and gradual exhaustion of the myocardium would quickly lead to the development of heart failure. Future studies need to assess whether such changes in cardiomyocyte renewal may be the cause or consequence of certain types of cardiomyopathies.
Sources of new cardiomyocytes
While cardiomyocyte renewal shown by 14 C birth dating appears to be insufficient to compensate for the extreme loss of functional heart muscle tissue following myocardial infarction, investigating the underlying mechanisms and sources of postnatally born myocytes may offer new therapeutic strategies targeting these endogenous cardiomyocyte regeneration pathways.
According to our current knowledge, there are two potential sources of newly formed cardiomyocytes: pre-existing cardiomyocytes that undergo dedifferentiation and duplication, and stem or progenitor cells that give rise to de novo cardiomyocytes. Animal studies provide evidence for either mechanism, although the biological significance of these regenerative processes has been debated. 20, 30 Myocyte duplication has been documented in injured amphibian and zebrafish hearts as well as in murine hearts, albeit at a much lower rate. Long-term infusion of the non-toxic nucleotide analogue 15 Nthymidine allowed for labelling and identification of cycling cardiomyocytes in mouse hearts through multi-isotope imaging mass spectrometry. 21 Excluding binucleation and polyploidy events, Senyo et al. 21 demonstrated that 0.76% of all cardiomyocytes in the left ventricle are exchanged within 1 year in the young adult animal. This process was augmented after cardiac infarction, suggesting activation of regenerative pathways upon injury. Myocyte renewal in the mouse heart seems to be age related, as it is in the human heart. 22 The highest renewal rates were observed in neonatal mice 21, 35, 63 with improved regenerative capacity and reduced scarring within the first post-natal week upon apical resection and ischaemic injury. 23, [76] [77] [78] Any injury induced later leads to substantial scar formation and impaired heart function. Although the regenerative response in the neonatal mouse heart has been successfully demonstrated by several research groups, 15, [20] [21] [22] 21, 63 technical discrepancies in the surgical procedure and resection of larger portions of the myocardium have led to differences in the amount of scarring and recovery. 75, 79, 80 The existence of this regenerative window and its duration have yet to be examined in large animals and human neonates. Apart from cycling cardiomyocytes, several other cell types, including cardiac progenitor cells, have been suggested as potential sources of this renewal process. Several endogenous cell populations that harbour stem cell characteristics have been described in the mammalian heart and could contribute to its endogenous regenerative capacity. 81 Cardiac progenitor cells comprise distinct cell types characterized by the expression of c-kit, Sca-1, ABCG2 (SP cells), Islet-1, or Tbx18 (epicardial progenitor cells); [82] [83] [84] [85] [86] however, there is overlap between these populations across different studies, which makes the interpretation of experimental data problematic. Although these various cell populations have been described to possess the ability to give rise to cardiomyocytes, as well as to endothelial and smooth muscle cells post-natally, 83, 84 recent genetic lineage tracing studies have challenged this view.
These fate-mapping experiments, using constitutive and inducible genetic cell tracing systems, demonstrated a minimal contribution of endogenous Sca-1 þ87 or c-kit þ cells to the adult cardiomyocyte population.
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Stimulating cardiomyogenesis
Increasing evidence supports that differentiated cardiomyocytes of the functional myocardium contribute to the generation of new cardiac cells through dedifferentiation or re-entry into the cell cycle. 21 Several promoting factors have emerged as potential initiators and drivers of the dedifferentiation process and cell cycle re-entry in mammalian cardiomyocytes.
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Figure 5 The human heart throughout life. Overview of age-related changes in cardiomyocyte number, multinucleation, polyploidy, and cardiomyocyte renewal in the human heart. Direct manipulation of the cell cycle through the modification of activity or expression of well-known regulatory proteins offers an obvious yet challenging way to enhance proliferation of distinct cell types. Overexpression of several different members of the cell cycle machinery has been studied in the context of myocardial regeneration lately. 94 In a recent study, overexpression of cyclin A2 in transgenic mice increased the rate of cardiomyocyte mitoses during early post-natal development and resulted in better systolic function following cardiac infarction compared with wild-type controls. [95] [96] [97] [98] Moreover, when cyclin A2 was introduced by adenoviral transfection to the infarct border zone following experimental cardiac infarction in adult rats and in a porcine model, substantial cardiomyocyte regeneration and functional improvement could be observed. 95, 96, 99 Recent studies have demonstrated that changes in oxygen concentration and, consequentially, in the level of reactive oxygen species in cardiomyocytes impact their regenerative potential. 100 Hypoxic cardiomyocytes were genetically labelled and traced using the oxygendependent degradation domain of Hif-1a in the adult mouse heart. These hypoxic myocytes show a higher capacity to proliferate and contribute to turnover in the adult myocardium. 101 Moreover, when adult mice are exposed to gradual chronic hypoxia, cardiomyocyte proliferation is induced, leading to improved recovery following myocardial infarction. 102 Regardless of their molecular characteristics, the method of delivery and subsequent kinetics of potential pro-proliferative compounds are of primary importance. A recent advancement has been the introduction of a novel delivery method, the injection of modified RNA (modRNA). These molecules contain substituted nucleotides that are responsible for the increased transfection efficiency and lower cytotoxicity of modRNA in primary cells. 103 In an important study aiming to investigate the applicability of these compounds in treating ischaemic heart diseases, vascular endothelial growth factor (VEGF) modRNA was injected into murine hearts at the time of experimental myocardial infarction, reducing the infarct size, enhancing neovascularization, and improving heart function at 3 weeks postinfarction and survival for over 1 year. 104 Growing evidence suggests that the otherwise quiescent epicardium becomes reactivated upon injury and contributes to the regenerative response. 105 Recently, follistatin-like 1 (Fstl1) has been identified as a secretion product of epicardial mesothelial cells. 66 When human Fstl1 protein is applied via an epidural patch over the ischaemic myocardium, cell cycle re-entry and division can be observed in pre-existing cardiomyocytes in mice and swine models.
Future studies need to demonstrate whether administration of Fstl1 may be an effective therapeutic strategy following myocardial infarction in humans. Some of the previously mentioned approaches rely on forced expression of certain proteins, which requires genetic manipulation of cardiomyocytes or their potential progenitor cells. The administration of external nucleotide sequences coding well-defined transcription factors-often in the form of viral particles-has been the traditional approach for modifying and differentiating cardiomyocytes from iPSCs. However, several groups have recently described the use of small molecules to induce targeted differentiation of iPSCs. Different combinations, or so-called 'cocktails', of small molecular compounds have been found to chemically induce the formation of cardiomyocyte-like cells in vitro, which hold the potential to be transplanted into living animals. 106 Additionally, direct transdifferentiation of fibroblasts into cardiomyocytes has also been described using such compounds, which potentially obviates the need for the intermediate, dedifferentiated iPSC stage. 107, 108 Recently, a computational method was designed, which was aimed at discovering effective combinations of such small molecules to drive cardiomyocyte differentiation. 109 
Conclusions
In recent years, a growing body of evidence demonstrated that, in contrast to our classical view, the adult heart is not a post-mitotic organ; instead, it retains its capacity to generate new cardiomyocytes throughout adulthood.
Although the age and turnover dynamics of human cardiomyocytes could be established using 14 C birth dating and mathematical modelling ( Figure 5 ), little is known about how de novo cardiomyogenesis is regulated in the adult human heart. 21, 32 The abundance of experimental approaches aimed at stimulating endogenous cardiomyocyte renewal illustrates this increasing interest. Unveiling the physiological processes that underlie the endogenous regenerative potential of the human heart could provide a basis for therapeutic approaches to promote significant cardiomyocyte renewal in various cardiovascular pathologies.
